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Airwaymucushypersecretion(AMH)isakeypathophysiologicalfeatureofchronicairwayinﬂammatorydiseasessuchasbronchial
asthma, cystic ﬁbrosis, and chronic obstructive pulmonary disease. AMH contributes to the pathogenesis of chronic airway
inﬂammatory diseases, and it is associated with reduced lung function and high rates of hospitalization and mortality. It has
been suggested that AMH should be a target in the treatment of chronic airway inﬂammatory diseases. Recent evidence suggests
that a key regulator of airway inﬂammation, hyperresponsiveness, and remodeling is peroxisome proliferator-activated receptor
gamma (PPARγ), a ligand-activated transcription factor that regulates adipocyte diﬀerentiation and lipid metabolism. PPARγ is
expressed in structural, immune, and inﬂammatory cells in the lung. PPARγ is involved in mucin production, and PPARγ agonists
can inhibit mucin synthesis both in vitro and in vivo. These ﬁndings suggest that PPARγ is a novel target in the treatment of AMH
and that further work on this transcription factor may lead to new therapies for chronic airway inﬂammatory diseases.
1.Introduction
Airway mucus hypersecretion (AMH) is a common patho-
logical feature in chronic airway inﬂammatory diseases such
as asthma, chronic obstructive pulmonary disease (COPD),
and cystic ﬁbrosis (CF). Growing studies have suggested that
AMH is associated with the progression of chronic airway
inﬂammatory diseases and it is a signiﬁcant contributor to
morbidity and mortality. To control, AMH plays an impor-
tant role in the treatment of chronic airway inﬂammatory
diseases; however, eﬀective therapies that target AMH are
lacking [1, 2].
Peroxisome proliferator-activated receptors (PPARs) are
a family of ligand-activated transcription factors belonging
to the nuclear hormone receptor family. PPARs are related
to retinoid, glucocorticoid, and thyroid hormone receptors
[3]. They regulate diverse physiological processes, such as
lipid biosynthesis and glucose metabolism, by binding to
sequence-speciﬁc PPAR response elements in the promoter
regionoftargetgenes.Recently,PPARsandtheirligandshave
been found to inhibit the expression of proinﬂammatory
genes, implicating them as regulators of immune and
inﬂammatory responses. Several studies have demonstrated
that PPAR ligands possess anti-inﬂammatory properties that
may prove useful in the treatment of inﬂammatory lung
diseases [4–6].
PPARγ is the most extensively studied PPAR subtype.
It is involved in a series of lung diseases, including lung
ﬁbrosis, pulmonary vascular diseases, acute lung injury, and
lung cancer [7–10]. Besides its regulatory role in adipocyte
diﬀerentiation,glucose,andlipidmetabolism,PPARγ activa-
tionreducesthesynthesisandreleaseofimmunomodulatory
cytokines from various cell types that participate in the regu-
lation of inﬂammatory and immune processes. Speciﬁcally,
mounting evidence suggests that PPARγ plays important
roles in regulating processes related to airway inﬂammation,
airway remodeling, and airway hyperresponsiveness, indi-
cating that PPARγ and its ligand show potential as targets
to develop treatments for chronic airway inﬂammatory
diseases [11]. In fact, PPARγ has been implicated in AMH.
Recentstudies have shown that chronic airway inﬂammatory
diseases in humans are associated with altered PPARγ2 PPAR Research
expression and that PPARγ ligand can attenuate AMH in
both in vitro and in vivo experimental models. This paper
will summarize recent work implicating PPARγ in AMH.
2.AMH andChronicAirway
InﬂammatoryDiseases
2.1. Signiﬁcance of AMH. Mucus secretion is essential for
protectingairways.Itisvitalforairhumidiﬁcation,warming,
and cleaning [12]. However, in patients with chronic airway
inﬂammatory diseases, excessive mucus is secreted into the
airway, which leads to hospitalization and death in many
patients. This hypersecretion, termed AMH, obstructs the
airways, limits airﬂow, impairs gas change, and causes
ventilation-perfusion mismatch. Patients with chronic air-
way inﬂammatory diseases that also present with AMH
generally have poor lung function and high rates of hos-
pitalization and death. Compromised mucociliary function
can reduce mucus clearance, which can encourage bacterial
colonization, leading to chronic pulmonary infections and
exacerbations. In addition, chemicals synthesized by bacteria
or released when bacteria are degraded by the immune
system can stimulate mucin synthesis and mucus secretion,
resulting in a vicious circle [1, 13].
Studies suggest that AMH is not merely a clinical
symptom but instead a critical factor in the pathogenesis
of chronic airway inﬂammatory diseases. AMH is associated
with greater susceptibility to COPD, a decline in forced
expiratory volume in one second, hospitalization, and excess
mortality [14–16]. The incidence of COPD in young adults
presenting with AMH symptoms is three-fold higher than
that in subjects who have never reported AMH symptoms,
regardless of their smoking habits [17]. These ﬁndings are
supportedbyananalysisoftheFraminghamoﬀspringcohort
studies [18].
AMH has long been recognized as a major cause of death
in asthma. One study found luminal occlusions covering
20–100% of the cross-sectional area in patients who died
from asthma, leading the authors to conclude that luminal
obstruction of airways by an exudate composed of mucus
and cells is a major contributor to asthma fatality [19]. In
addition, AMH symptoms such as chronic cough or phlegm
are independently and signiﬁcantly related to uncontrolled
asthma, and a history of persistent symptoms related to
AMH is associated with a more severe asthma phenotype
[20]. AMH also contributes to morbidity due to cystic
ﬁbrosis (CF). In CF patients, the reduced ability of epithelial
cells to secrete chloride usually leads to reduced mucus
accumulation in the airways, which favors chronic infection
by Pseudomonas aeruginosa and other organisms. AMH
contributes to CF morbidity by increasing the frequency and
severity of pulmonary infections as well as by impairing lung
function [21].
2.2. Inﬂammation and AMH. Abnormal inﬂammatory
response is the major component of chronic airway inﬂam-
matory diseases. Such inﬂammatory response has been
associated with AMH in airway diseases. Numerous studies
have demonstrated that inﬂammatory stimuli and medi-
ators/cytokines contribute to excess mucin synthesis and
mucus secretion in airways. For instance, cigarette smoke,
neutrophil elastase, and P. aeruginosa proteases are well-
known inﬂammatory stimuli that can cause signiﬁcant
inﬂammatory responses, which result in goblet cell meta-
plasia and hyperplasia, leading in turn to mucin over-
production and mucus hypersecretion in airways [22–24].
Inﬂammatory cytokines such as tumor necrosis factor-α
(TNF-α), interleukin (IL)-1β, IL-6, IL-8, IL-13, and IL-17
can upregulate the expression of MUC5AC, the marker of
goblet cell metaplasia, through diﬀerent signaling pathways
[25–29].Thisisthemostimportanteventinthepathogenesis
of AMH. Thus, the ability to control airway inﬂammatory
responses should reduce AMH and thereby beneﬁt patients
with chronic airway inﬂammatory diseases. However, cur-
rent anti-inﬂammatory treatments with corticosteroids are
noteﬀectiveinallpatientswithchronicairwayinﬂammatory
diseases. Thus, the search for novel drug targets for these
diseases continues.
In summary, AMH arising as a result of inﬂammatory
processes can lead to physiologically and clinically measur-
able mechanical airway obstruction in patients with chronic
airwayinﬂammatorydiseases.Inthisway,AMHsigniﬁcantly
aﬀects the pathogenesis, progression, and prognosis of these
diseases. Therapiesthataim to controltheinﬂammation that
triggers AMH may be eﬀective at treating chronic airway
inﬂammatory diseases [30–32].
3. Expressionand Anti-InﬂammatoryRole of
PPARγ inthe Lung
3.1. Expression of PPARγ in Lung Cells. PPARγ is expressed
in many types of structural cells in the lung, including
ﬁbroblasts, ciliated airway epithelial cells, alveolar type II
pneumocytes, and airway smooth muscle cells [3, 4, 32].
As t u d yi nP P A R γ-knockout mice has highlighted the role
of this transcription factor in animal models. A speciﬁc
PPARγ deletion in airway epithelium produced persistent
enlargement of the airspaces in adult mice, which showed
more severe emphysema symptoms and higher macrophage
numbers after exposure to cigarette smoke than did mice
carrying the PPARγ gene [33]. These results suggest that
epithelial PPARγ is required for proper lung maturation and
response to injury.
PPARγ is also present in several types of inﬂammatory,
immune cells in the lung, where it exerts anti-inﬂammatory
and immuno-modulatory eﬀects. Specially, PPARγ has been
found in macrophages, eosinophils, T cells, B cells, and
dendritic cells [34–38]. It plays an anti-inﬂammatory role
in lung cells mainly by inhibiting cytokine production and
enhancing phagocytosis of apoptotic neutrophils, a process
essential to resolve inﬂammation.
Increasing evidence suggests that altered PPARγ expres-
sion and function may be associated with chronic airway
inﬂammatory diseases and that stimulation of this receptor
may attenuate inﬂammatory responses. A study examining
the expression of PPARγ in lung tissues of patients with
COPD found the protein to be present mainly in alveolarPPAR Research 3
epithelial cells and smooth muscle cells in the bronchial
walls. The intensity of PPARγ was inversely proportional to
the severity of the COPD, with the signal stronger in patients
with milder COPD [39]. Another study found that PPARγ is
expressed in CF- and non-CF-type human airway epithelial
cells, but appears to be either less abundant, less functional
in binding its target DNA sequence, or both, in CF [40].
In asthmatic individuals, but not healthy objects, segmental
allergen challenge led to downregulation of PPARγ mRNA
and protein expression in alveolar macrophages [41]. These
ﬁndings are suggestive of a role for PPARγ agonists in the
treatment of chronic lung inﬂammatory diseases.
3.2. The Anti-Inﬂammatory Role of PPARγ. Building on the
evidence linking PPARγ and airway inﬂammatory diseases,
several studies have investigated the therapeutic role of the
receptor and its ligand in cellular and animal models of these
diseases. Administration of PPARγ ligand to BALB/c mice
sensitized and challenged with ovalbumin (OVA) reduced
the levels of proinﬂammatory mediators in bronchoalveo-
lar lavage ﬂuid (BALF) and attenuated the inﬂammatory
response in the lung [35, 42, 43]. Treating human airway
epithelial cell line A549 with the PPARγ agonist troglitazone
blocked the ability of phorbol 12-myristate 13-acetate to
stimulate an increase in TNF-α levels. However, this eﬀect of
troglitazone required the presence of MUC1/Muc1 [44]. The
authors concluded that PPARγ exerts an anti-inﬂammatory
eﬀect by stimulating MUC1/Muc1 expression, which then
blockstheproductionofTNF-α/IL-8inducedbyphorbol12-
myristate 13-acetate in airway epithelial cells [44]. In addi-
tion, PPARγ plays an essential role in the pathway through
which monocyte/macrophage-derived microparticles acti-
vate NF-κB and ultimately induce upregulation of proin-
ﬂammatory mediators in human lung epithelial cells [45].
The anti-inﬂammatory eﬀect of PPARγ is thought to
be due mainly to its ability to downregulate proinﬂam-
matory gene expression. It does so by sequestering shared
coactivators, reducing the ability of inﬂammatory tran-
scription factors to bind their target DNA. The second
wayisthroughligand-dependenttransrepression,preventing
other transcription factors’ association with DNA sequences.
At the same time, PPARγ can increase the transcription
of anti-inﬂammatory genes. Agonist binding to PPARγ
induces a conformational change in the receptor, allowing
the dissociation of corepressors and the association of
coactivator molecules. This allows the formation of PPARγ
dimmers or heterodimers and subsequent interaction with
peroxisome proliferator response elements, which increases
anti-inﬂammatory gene transcription [46].
Taken together, these ﬁndings suggest that PPARγ par-
ticipates in both physiological and pathological processes in
chronic airway inﬂammatory diseases. These studies make a
strong case for PPARγ activation as a potential treatment for
chronic airway inﬂammatory diseases.
4. PPARγ andAMH
Since the inﬂammatory response is the major contributor
to AMH, and PPARγ and its ligand help regulate airway
inﬂammation, several studies have investigated the potential
involvement of PPARγ and its ligand in AMH.
Lee and colleagues carried out the ﬁrst study to examine
the role of PPARγ l i g a n do nm u c i np r o d u c t i o ni nh u m a n
airway epithelial NCI-H292 cells exposed to cigarette smoke
[47]. Exposure caused a signiﬁcant increase in TNF-α and
MUC5AC production, which was attenuated by adminis-
tration of the PPARγ agonist rosiglitazone. Rosiglitazone
increased the expression of phosphatase and tensin homolog
deleted on chromosome 10 (PTEN) and inhibited the
PI3K/Aktpathway.PTENantagonizesPI3K-mediatedsignal-
ing,whoseroleinmucinproductioniswelldocumented [47,
48]. These results provide the ﬁrst evidence that a treatment
targeting PPARγ can signiﬁcantly inhibit cigarette smoke-
induced mucin production, raising the possibility that this
approach may be useful in the clinic. Indeed, the study
authors proposed that using a PPARγ agonist to activate
PTEN and inhibit PI3K/Akt may be a potential therapy for
cigarette smoke-induced mucin secretory diseases [47].
Subsequent studies evaluated the eﬀect of rosiglitazone
on airway mucin production in animal models of AMH.
Exposingratsfortwoweekstoacrolein,oneofthemosttoxic
components in cigarette smoke, induced goblet cell hyper-
plasia in bronchial epithelium and upregulated MUC5AC
mRNA and protein expression in rat lungs. These changes
were associated with airway inﬂammation, as evidenced by
the increased numbers of inﬂammatory cells and levels of
inﬂammatory cytokines (IL-1β,I L - 8 ,a n dT N F - α)i nB A L F .
Treating the rats with rosiglitazone before acrolein exposure
attenuated these changes in a dose-dependent manner
[49]. Rosiglitazone has also been shown to inhibit NF-κB
activation, which is well known to play an important role
in regulating not only multiple inﬂammatory cytokines but
also AMH in inﬂammatory lung diseases [50, 51]. Therefore,
inhibition of NF-κB activation by rosiglitazone may explain
the observed downregulation of proinﬂammatory mediators
and the reduction in AMH. From these ﬁndings, Liu et al.
concluded that ligand-induced activation of PPARγ may be
a novel therapy for AMH in chronic airway inﬂammatory
d i s e a s e ss u c ha sC O P D[ 49].
AMH is also an important pathologic feature of asthma,
which is characterized by nonspeciﬁc airway inﬂammation.
Several studies have examined the involvement of PPARγ
and its ligand on AMH in a mouse model of asthma.
AMH was observed in airways of animals sensitized and
challenged with OVA, while it was barely detectable in
airways of nonsensitized animals. Administration of the
PPARγ agonist ciglitazone via nebulizer reduced OVA-
induced mucus gland hyperplasia and airway occlusion due
to mucus hypersecretion by approximately 75% [52]. In a
diﬀerent mouse model, mice were exposed or not to toluene
diisocyanate to induce asthma. Exposed mice that received
PPARγ agonists(rosiglitazoneorpioglitazone)oradenovirus
carryingPPARγ2cDNAshowedalowerpercentageofairway
epithelium staining positive with PAS than did exposed mice
that did not receive agonists or adenovirus [53]. In addition,
both of these studies found that PPARγ agonists support
protective remodeling of the airway wall by regulating TGF-
β or TGF-β1 and collagen deposition. Results from both of4 PPAR Research
these mouse models support the possibility of using PPARγ
agonist to treat AMH in humans.
In addition to these observations in cell lines or animal
models, several lines of indirect evidence link activation of
PPARγ and AMH. Activation of PPARγ by rosiglitazone or
pioglitazone markedly reduced mRNA expression of matrix
metalloproteinase-9(MMP-9)andinhibitedTNF-α induced
MMP-9gelatinolyticactivity[54].SinceMMP-9isanimpor-
tant MMP related to AMH [55], these results suggest that
PPARγ may attenuate AMH through a pathway involving
MMP-9. Simvastatin is a statin that modulates inﬂammatory
processes and that can inhibit mucin production and AMH
[56]. A recent study indicated that its anti-inﬂammatory
eﬀect may involve PPARγ activation [57], which means that
simvastatin may suppress AMH via a mechanism mediated
by PPARγ. It seems clear from these diverse lines of evidence
that the eﬀects of PPARγ and its ligand on AMH are
mediatedbymultiplemechanisms.Furtherworkisneededto
identify new ligands of PPARγ and investigate the signaling
pathways aﬀected by the receptor.
In summary, substantial evidences indicate that PPARγ
is involved in AMH and that PPARγ ligand suppresses AMH
by inhibiting proinﬂammatory cytokines and inﬂammatory
signaling pathways. Therefore, PPARγ agonists may have
potential as treatments for AMH in chronic airway inﬂam-
matory diseases.
5. Considerations for Targeting PPARγ in
the Treatment of AMH
Although several studies have suggested that PPARγ is
involved in AMH and that PPARγ agonists inhibit AMH,
there is still a long road ahead before laboratory studies can
be translated to the clinic. For one thing, the pathogenesis
of chronic airway inﬂammatory diseases such as COPD,
asthma, and CF is extremely complicated. Only a fewstudies,
most of them descriptive, have directly investigated the role
of PPARγ and PPARγ ligand in AMH. As a result, the
signaling pathways aﬀected by PPARγ or PPARγ agonists
remain poorly understood. Further investigation of these
a r e a sw i l lb er e q u i r e dt od e ﬁ n et h ee ﬀects of PPARγ ligands
on airway epithelial cells and the mechanisms by which these
pro- and/or anti-inﬂammatory responses occur.
A second consideration for targeting PPARγ in the clinic
is that the route of PPARγ agonist administration may be
important. In Honda’s study [52], treating Balb/c mice with
nebulizedciglitazoneledtoareductioninmucusproduction
in the airways, whereas orally administered ciglitazone
had no such eﬀect [58]. Oral gavage of rosiglitazone or
pioglitazone reduced toluene diisocyanate-induced AMH in
Balb/c mice [53], while oral rosiglitazone treatment had no
eﬀectongobletcellhyperplasiainC57BL/6mice[59].Future
work should clarify whether the diﬀerent results observed
with diﬀerent agonists or models of administration reﬂect
diﬀerences in the sensitivity of mouse strains to regulation of
airway inﬂammation and AMH, or whether agonist identity
and mode of administration are crucial.
Finally, the safety of PPARγ agonists in patients with
chronic airway inﬂammatory disease should be carefully
examined. Recent studies suggest an association between
rosiglitazone treatment and increased risk of cardiovascular
events in patients with type 2 diabetes [60, 61]. Thus it
remains to be seen whether PPARγ agonist is safe for patients
with chronic airway inﬂammatory diseases.
6. Summary
The present paper describes the clinical importance of AMH
in the pathogenesis of chronic airway inﬂammatory diseases
andmakesthecaseforexploringPPARγ andPPARγ ligandas
potential target in treating AMH. Corticosteroid is the ﬁrst-
line anti-inﬂammatory drug used to chronic airway inﬂam-
matory diseases, but its therapeutic eﬀects are controversial,
and physicians have begun to pay attention to its undesirable
side eﬀects [62]. In fact, it is generally accepted that steroids
have only limited eﬀects on AMH [63], so there is a demand
for novel and eﬀective anti-inﬂammatory drugs that can
reduce AMH. Increasing evidence suggests that PPARγ is
involved in mucin production and that PPARγ agonists
inhibit AMH both in vitro and in vivo. Indeed, a recent
clinical trial found that rosiglitazone improved lung function
in steroid-resistant asthma patients [64], providing direct
evidence that patients with chronic airway inﬂammatory
diseases can beneﬁt from PPARγ agonist treatment. Thus,
PPARγ agonists may represent a novel class of pharmaco-
logical agents useful in the management of AMH in chronic
airway inﬂammatory diseases.
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